现型药物发现:对于thymosin alpha-1的一个案例
Enrico Garaci1, Maurizio Paci2, Claudia Matteucci3
1San Raffaele Sulmona, L'Aquila, Italy.
Frontiers in medicine
|June 21, 2024
概括
现型药物发现 (PDD) 选功能效应的化合物,绕过已知的分子标的需要. 这种方法,以蒂莫辛α-1研究为例,为确定精准医学中的新疗法提供了一个强有力的策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
- 系统生物学 系统生物学
背景情况:
- 现型药物发现 (PDD) 基于观察到的效果来选化合物,而不是基于标的药物发现,需要对分子标的先验知识.
- PDD非常适合具有多因素机制的复杂疾病,与基于症状的疾病定义保持一致.
- 大数据分析的近期进展使PDD恢复活力,使得尽管面临诸如目标解密等挑战,但取得了重大成就.
研究的目的:
- 探索在精准医学背景下表型药物发现 (PDD) 的应用.
- 在PDD框架内,讨论一下甲状腺类激素 - - 甲状腺素α-1的治疗效用.
- 通过专注于功能性结果,突出PDD在发现具有意想不到应用的药物的潜力.
主要方法:
- 对提莫辛α-1.1的临床前和临床研究的综述.
- 对复杂疾病和宿主微生物相互作用的PDD策略的分析.
- 讨论将PDD与大数据集成用于命中验证和目标解卷.
主要成果:
- 通过专注于功能性结果而不是预定义的目标,PDD可以发现具有新疗效的药物.
- 蒂莫辛α-1作为PDD的案例研究,证明了其在临床前和临床环境中的潜力.
- PDD框架可以适应涉及多种代谢物和标的疾病的复杂性,例如宿主微生物相互作用.
结论:
- 现型药物发现为识别治疗方法提供了一种有价值的方法,特别是对于复杂的疾病,其中的机制尚未完全理解.
- 硫素α-1的治疗潜力可以在PDD范式内有效地探索和利用,特别是在精密医学中.
- 整合PDD与大数据分析对于克服挑战和实现这种药物发现战略的全部潜力至关重要.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K


